Business Wire

OR-AIRSHIP

29.10.2020 09:32:07 CET | Business Wire | Press release

Share
Airship Journeys Powers Massive Conversion Gains for Brands Across the Globe

Customer engagement company Airship today detailed the amazing success three brand marketers have achieved using Airship Journeys to more quickly and easily improve the business impact of cross-channel customer journeys. The customer journeys these marketers have optimized have driven double- and even triple-digit percentage performance improvements over baselines established by control groups.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005340/en/

Airship Journeys combines everything marketers need to create, evaluate, test and optimize cross-channel customer engagement journeys in a single, intuitive visual UI. Only Airship Journeys allows marketers to zoom in from glanceable, color-coded visualizations of journey performance against business goals and baselines, to view and optimize any underlying message with A/B testing.

As the largest professional social network and digital distribution platform for musicians and other creative types, Vampr has created numerous journeys since selecting Airship in August 2020. A recently launched reactivation journey targets app users who have been inactive for five days with a series of three push notifications and a final email within two weeks, and has been found to reactivate users at a 277 percent higher rate than those in the control group.

“My goal is to drive critical business KPIs by getting users to complete their profiles, connect with nearby creatives, add their original songs and videos, and much more — 90 percent of the time I’m using Airship Journeys to optimize these user experiences,” said Jessy Trengove, head of insights, Vampr. “By being able to easily see journey performance against baseline metrics and control groups, I’m more easily able to achieve the goals that make a real difference to the business.”

On Black Friday, J. C. Penney Company, Inc. used Airship Journeys to transform a one-message cart abandonment automation into a two-message journey and found significant lift in completed purchases. This cart abandonment journey now shows an all-time increase of 40 percent higher purchase completion rates over the control group baseline. JCP reactivation messages spread across three separate automations are now being combined into a single journey, enabling a goal-based view of business impact rather than trying to draw conclusions by comparing each message’s engagement metrics.

“With Airship Journeys, we can see where each customer comes into and progresses through each phase and can more easily A/B test any message in the journey to optimize timing, triggers, copy and content,” said Haley Welmon, owned media specialist, JCPenney. “Airship Journeys control groups and baselines help us make decisions and increase revenue more quickly, so we can maximize our success and ensure that what we think is the best experience for the customer, actually is.”

In hospitality, in their mobile app, Radisson Hotel Group has created a cart abandonment journey series spanning three messages over four days — the first of which guarantees the room’s rate — driving an 11 percent lift in completed reservations over the control group.

Tune in to the webinar, “Creating Extraordinary Customer Journeys with a Culture of Experimentation,” live Thursday, October 29 at 10am PDT / 1pm EDT / 5pm GMT / 6pm CET (recording available to registrants), and learn how to gain advantage by experimenting, testing and optimizing critical cross-channel customer journeys.

“It’s so gratifying to see how quickly brands have realized substantial business gains due to the powerful way we’ve reinvented cross-channel journeys for the mobile era,” said Brett Caine, CEO and president, Airship. “Engaging customers with in-the-moment relevancy across digital channels has never been more important, and small improvements can drive big results. Airship Journeys brings breakthrough simplicity to the entire process and speeds insights-to-optimization to accelerate revenue growth.”

Recently, Airship was named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category (tied) and the second highest score in the Current Offering category.

About Airship

Thousands of the world’s leading brands rely on Airship to spark closer connections with their customers through highly contextual and relevant interactions. Only Airship’s Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, not which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.

With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.

For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye